Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model
Top Cited Papers
Open Access
- 28 June 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (7) , 2422-2431
- https://doi.org/10.1002/art.22721
Abstract
Objective: To explore the relationship between changes in the severity of skin disease and morbidity and mortality in patients with diffuse cutaneous systemic sclerosis (dcSSc).Methods: From a large single‐center cohort, we identified 225 patients with dcSSc for whom serial clinical information was available from within 24 months of the onset of the first non–Raynaud's phenomenon manifestation of SSc. The end points analyzed included death and heart, lung, kidney, and gastrointestinal tract involvement. Latent linear trajectory modeling (LTM) was applied to identify patients with a similar trajectory of modified Rodnan skin thickness score (MRSS) changes over the first 3 years of followup. Clinical outcomes were compared between 3 different LTM subgroups.Results: LTM permitted classification of 131 patients (58%) into 1 of 3 subgroups with different skin score trajectories. Survival was lowest in the subgroup of patients who had a high baseline skin score and experienced little improvement during followup (P = 0.003). However, the frequency of clinical end points was similar in the subgroup with the most favorable trajectory (i.e., a low initial MRSS and subsequent improvement) and the subgroup with a high baseline MRSS and no improvement. Interestingly, the end point frequency was greatest in the subgroup with a high initial MRSS and subsequent improvement, suggesting that sustained severe skin disease does not necessarily predict the number of visceral complications, and that the relationship between the skin score and internal organ involvement in dcSSc is more complex than previously thought.Conclusion: Although mortality was highest among patients with the worst skin‐related outcomes, no simple relationship between burden of disease and change in skin score was observed.Keywords
This publication has 20 references indexed in Scilit:
- Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192Arthritis & Rheumatism, 2007
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- Predictors and outcomes of scleroderma renal crisis: The high‐dose versus low‐dose D‐penicillamine in early diffuse systemic sclerosis trialArthritis & Rheumatism, 2002
- Non-invasive measurement of biomechanical skin properties in systemic sclerosisAnnals of the Rheumatic Diseases, 2002
- Improvement in skin thickening in systemic sclerosis associated with improved survivalArthritis & Rheumatism, 2001
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trialArthritis & Rheumatism, 2000
- COMPARISON OF METHOTREXATE WITH PLACEBO IN THE TREATMENT OF SYSTEMIC SCLEROSIS: A 24 WEEK RANDOMIZED DOUBLE-BLIND TRIAL, FOLLOWED BY A 24 WEEK OBSERVATIONAL TRIALRheumatology, 1996
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980
- Skin thickness and collagen content in progressive systemic sclerosis and localized sclerodermaArthritis & Rheumatism, 1979